Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02602834
Other study ID # 2015/97/REK sør-øst A
Secondary ID
Status Completed
Phase N/A
First received October 6, 2015
Last updated November 9, 2016
Start date May 2015
Est. completion date November 2015

Study information

Verified date November 2016
Source Oslo University Hospital
Contact n/a
Is FDA regulated No
Health authority Norway: Data Protection Authority
Study type Interventional

Clinical Trial Summary

High intensity Interval training (HIT) has repeatedly been documented to have superior positive effects on oxygen uptake and general physical health compared to continuous moderate exercise in healthy individuals and patients with heart disease. Recently, the same effect has been shown in heart transplanted recipients. Which mechanisms that explains this difference is uncertain; the effect can be due to changes in the heart or changes in the peripheral tissue and muscles. To explore these mechanisms the investigators will in this study compare two different exercise modalities, and explore how different biomarkers change in blood, related to exercise.


Description:

15 heart transplanted recipients (and 5 healthy controls) will be included in the study. Each patient will have three study-days.

The study is designed to be a cross-over study. And randomisation will decide which training they will have som training session 1 and training session 2; Interval or continuous training.

Before starting the two training sessions they will measure oxygen uptake and baseline blood samples.

During each exercise session the patients will take blood samples during and after exercise.

After first study admission the patients will have a wash out period for 1 week until first training session, and another week until the last session.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria (HTx):

- 1-10 years after heart transplantation

- Lives in Oslo or near Oslo

- Stable health condition

- Optimal medical treatment/ medication

- No limiting physical handicap

- Written consent

Inclusion healthy control:

- No verified heart disease

- Willing to preform the study

- Over 18 years

- Written consent

Exclusion Criteria:

- Under 1 year or over 10 year since HTx.

- Lives far from Oslo

- Unstable health condition

- Not optimal medical treatment and/ or medication

- Limiting physical handicap

- Under 18 years

- Not written consent

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Other:
interval training
4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
moderate exercise
30 minutes (moderate intensity) aerobic exercise on treadmill without rest.

Locations

Country Name City State
Norway OUS- Rikshospitalet Oslo

Sponsors (2)

Lead Sponsor Collaborator
Oslo University Hospital Norwegian Health Association

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in crp with interval training compared to moderate training 1 week No
Primary Changes in interleukin levels with interval training compared to moderate training 1 week No
Primary Changes in ICAM levels with interval training compared to moderate training 1 week No
Primary Changes in MiRNA levels with interval training compared to moderate training 1 week No
Secondary Questionnaire of quality of life baseline No
Secondary Oxygen uptake V02 peak measured på exercise test on treadmill. baseline No
Secondary Questionnaire of physical activity baseline No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06035991 - First Clinical Evaluation of Heart Transplantation With Grafts Preserved Using an Ex-vivo Extended Perfusion System N/A
Recruiting NCT01927614 - Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy N/A
Recruiting NCT01705015 - Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement N/A
Completed NCT01655563 - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation Phase 2
Completed NCT01028599 - Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients N/A
Completed NCT00531921 - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival N/A
Terminated NCT00420537 - Shift to Everolimus (RAD) Kidney Sparing Study Phase 4
Enrolling by invitation NCT03292861 - The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients Phase 2
Recruiting NCT04924491 - Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children Phase 1/Phase 2
Recruiting NCT05270902 - Haemoadsorption During Heart Transplantation N/A
Completed NCT05289180 - Brachial Right Ventricle - Endomyocardial Biopsy
Recruiting NCT03687723 - Observational Study of the Clinical Use of the OCS™ Heart
Completed NCT01091194 - Effect of Exercise After Heart Transplantation Phase 2
Completed NCT01182571 - Exploration of Fatigue, Uncertainty, Depression and Quality of Life in Heart Transplantation Recipients N/A
Terminated NCT00678002 - Quality of Life in Pediatric Transplant Patients
Withdrawn NCT00780377 - Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients N/A
Withdrawn NCT00780637 - Brachial Artery t-PA Release in Heart Transplant Recipients N/A
Terminated NCT00121784 - Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients Phase 4
Withdrawn NCT00572286 - Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study N/A
Completed NCT00123331 - Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation Phase 4